Antigen binding protein against HER3

US11008402B2 · kind B2 · utility

Assignee

• UNIVERSITAT STUTTGART · DE

Inventors

• Roland Kontermann · Jeffery Road, DE
• Lisa Schmitt · Stuttgart, DE
• Meike HUTT · Stuttgart, DE
• Oliver SEIFERT · Stuttgart, DE
• Monilola Olayioye · Stuttgart, DE
• Michael Hust · Hannover, DE
• Stefan Dubel · Dossenheim, DE
• Jonas ZANTOW · Braunschweig, DE

Key dates

• Filing date: Sep 15, 2017
• Grant date: May 18, 2021
• Expiry date: Mar 5, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides an antigen-binding protein that specifically binds to a conformational epitope formed by domain III & IV of human epidermal growth factor receptor 3 (HER3) and antigen-binding proteins which compete therewith for binding, as well as fusion protein or conjugate comprising these. The invention also provides nucleic acid molecule comprising a sequence encoding said antigen binding proteins, vectors comprising the nucleic acid, and cells and pharmaceuticals comprising the antigen binding protein, the fusion protein, the nucleic acid, or the vector. The invention also provides the antigen binding protein, the fusion protein or conjugate, the nucleic acid, the vector, the cell, or the pharmaceutical for use as a medicament. The invention further provides a method of inhibiting tumor growth or treating cancer, comprising administering a therapeutically effective amount of the antigen binding protein, the fusion protein or conjugate, the nucleic acid, the vector, the cell, or the pharmaceutical.